CAS 1800046-95-0

Fórmula: C23H25N9O

InChI: InChI=1S/C23H25N9O/c24-21-12-25-11-19(28-21)20-13-32-6-5-26-23(32)22(29-20)27-16-1-3-17(4-2-16)30-7-9-31(10-8-30)18-14-33-15-18/h1-6,11-13,18H,7-10,14-15H2,(H2,24,28)(H,27,29)

Chave InChI: XCIGZBVOUQVIPI-UHFFFAOYSA-N

SMILES: C1CN(CCN1C2COC2)C3=CC=C(C=C3)NC4=NC(=CN5C4=NC=C5)C6=CN=CC(=N6)N

Lanraplenib

CAS: 1800046-95-0

Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.

Fórmula: C₂₃H₂₅N₉O

Pureza: 98.35%

Cor e Forma: Solid

Peso molecular: 443.5043

Ref: TM-T11824LL

Lanraplenib

CAS: 1800046-95-0

Lanraplenib

Fórmula: C₂₃H₂₅N₉O

Pureza: ≥98%

Peso molecular: 443.5

Ref: 54-BUP05400

6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

CAS: 1800046-95-0

Fórmula: C₂₃H₂₅N₉O

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 443.5043

Ref: IN-DA01LIG7

Lanraplenib

Produto Controlado

CAS: 1800046-95-0

Fórmula: C₂₃H₂₅N₉O

Cor e Forma: Neat

Peso molecular: 443.504

Ref: TR-L174615

Lanraplenib

CAS: 1800046-95-0

Lanraplenib is an experimental drug that has been shown to be effective in the treatment of autoimmune diseases. It is a small molecule that inhibits the activity of factor receptors and blocks the binding of cytokines and other inflammatory mediators to their receptors. Lanraplenib can be used for the treatment of chronic kidney disease, as well as systemic therapy for inflammatory diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. Lanraplenib has also been found to have a favorable safety profile in clinical trials.

Fórmula: C₂₃H₂₅N₉O

Pureza: Min. 95%

Peso molecular: 443.5 g/mol

Ref: 3D-AXC04695